Target intelligence / Profile preview

Aluminum ion (Al3+) (Al3+)

Target
Al3+
Molecular classification
Metal ion, Inorganic cation
01

Overview

Aluminum ions (Al3+) are non-essential trivalent cations that lack a known physiological role in human biology but represent a significant toxicological target, particularly in individuals with impaired renal function [21, 22]. In the gastrointestinal tract, aluminum absorption is typically low but can be significantly increased by the presence of citrates, which disrupt tight junctions and facilitate paracellular transport [14, 23]. Once in the systemic circulation, aluminum ions primarily bind to transferrin, allowing them to mimic iron and distribute to various tissues, most notably the bone matrix and the central nervous system [4, 19]. Chronic accumulation of aluminum leads to severe clinical manifestations, including dialysis encephalopathy, vitamin D-resistant osteomalacia, and microcytic anemia [6, 11, 12]. Therapeutic management of aluminum overload focuses on the use of chelating agents, such as deferoxamine, which bind the ions to form stable, water-soluble complexes that can be subsequently removed through the kidneys or via dialysis [5, 13, 24]. Monitoring of aluminum levels is critical in high-risk populations, such as those on long-term hemodialysis or receiving parenteral nutrition, to prevent irreversible organ damage [1, 11]. Furthermore, aluminum's interference with essential metal homeostasis and its pro-oxidant activity contribute to its systemic toxicity [4, 21].

Other names
Aluminum(3+)Al(III)Trivalent aluminumAluminum cation
02

Mechanism of action

Chelation of trivalent aluminum ions to form stable, water-soluble complexes (e.g., aluminoxamine) that are excreted renally or removed via dialysis.

03

Biological functions

Interference with iron homeostasisInhibition of bone mineralizationInduction of oxidative stressEnzyme inhibition
04

Disease associations

Aluminum toxicityDialysis encephalopathyOsteomalaciaMicrocytic anemiaChronic kidney disease-mineral and bone disorder (CKD-MBD)
05

Safety considerations

NeurotoxicityAdynamic bone diseaseInterference with iron metabolismEnhanced absorption in the presence of citratesAccumulation in renal impairment
06

Interacting drugs

Deferoxamine

2 more in the full profile.

07

Biomarkers

Serum aluminum concentrationDeferoxamine infusion testBone biopsy with aluminum stainingUrinary aluminum excretion

Beyond the preview

Go deeper on Aluminum ion (Al3+) (Al3+).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aluminum ion (Al3+) (Al3+).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call